Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.

Starbuck K, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, Stein J, Dransfield DT, Zarrella B, Growdon WB, Behrens J, Foster R, Rueda BR.

Oncotarget. 2018 May 1;9(33):23289-23305. doi: 10.18632/oncotarget.25289. eCollection 2018 May 1.

2.

MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma.

Cardozo ER, Foster R, Karmon AE, Lee AE, Gatune LW, Rueda BR, Styer AK.

Reprod Biol Endocrinol. 2018 May 11;16(1):46. doi: 10.1186/s12958-018-0364-8.

3.

Serum omega-3 fatty acids and treatment outcomes among women undergoing assisted reproduction.

Chiu YH, Karmon AE, Gaskins AJ, Arvizu M, Williams PL, Souter I, Rueda BR, Hauser R, Chavarro JE; EARTH Study Team.

Hum Reprod. 2018 Jan 1;33(1):156-165. doi: 10.1093/humrep/dex335.

PMID:
29136189
4.

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.

Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB, Rueda BR.

Gynecol Oncol. 2017 Jun;145(3):446-452. doi: 10.1016/j.ygyno.2017.03.006. Epub 2017 Mar 25.

5.

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity.

Prendergast JM, Galvao da Silva AP, Eavarone DA, Ghaderi D, Zhang M, Brady D, Wicks J, DeSander J, Behrens J, Rueda BR.

MAbs. 2017 May/Jun;9(4):615-627. doi: 10.1080/19420862.2017.1290752. Epub 2017 Feb 22.

6.

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.

Bajwa P, Nielsen S, Lombard JM, Rassam L, Nahar P, Rueda BR, Wilkinson JE, Miller RA, Tanwar PS.

Oncotarget. 2017 Jan 31;8(5):7265-7275. doi: 10.18632/oncotarget.13919.

7.

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.

Garrett LA, Growdon WB, Rueda BR, Foster R.

J Ovarian Res. 2016 Sep 15;9(1):58. doi: 10.1186/s13048-016-0267-2.

8.

MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma.

Guan Y, Guo L, Zukerberg L, Rueda BR, Styer AK.

Reprod Biol Endocrinol. 2016 Aug 17;14(1):45. doi: 10.1186/s12958-016-0180-y.

9.

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.

Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB.

Gynecol Oncol. 2016 Jun;141(3):570-579. doi: 10.1016/j.ygyno.2016.03.027. Epub 2016 Apr 1.

PMID:
27017985
10.

Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors.

Clark NC, Friel AM, Pru CA, Zhang L, Shioda T, Rueda BR, Peluso JJ, Pru JK.

Cancer Biol Ther. 2016;17(3):262-71. doi: 10.1080/15384047.2016.1139240. Epub 2016 Jan 19.

11.

The Epidemiology and Genetics of Uterine Leiomyoma.

Styer AK, Rueda BR.

Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:3-12. doi: 10.1016/j.bpobgyn.2015.11.018. Epub 2015 Dec 2. Review.

PMID:
26725703
12.

The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease.

Roussel-Gervais A, Couture C, Langlais D, Takayasu S, Balsalobre A, Rueda BR, Zukerberg LR, Figarella-Branger D, Brue T, Drouin J.

J Clin Endocrinol Metab. 2016 Feb;101(2):513-22. doi: 10.1210/jc.2015-3324. Epub 2015 Dec 22.

PMID:
26695862
13.

Characterization of extracellular DDX4- or Ddx4-positive ovarian cells.

Hernandez SF, Vahidi NA, Park S, Weitzel RP, Tisdale J, Rueda BR, Wolff EF.

Nat Med. 2015 Oct;21(10):1114-6. doi: 10.1038/nm.3966. No abstract available.

PMID:
26444630
14.

The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Diver EJ, Foster R, Rueda BR, Growdon WB.

Oncologist. 2015 Sep;20(9):1058-68. doi: 10.1634/theoncologist.2015-0149. Epub 2015 Jun 22. Review.

15.

Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB.

Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.

16.

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR.

Gynecol Oncol. 2015 Apr;137(1):160-6. doi: 10.1016/j.ygyno.2015.01.533. Epub 2015 Jan 17.

17.

Notch signaling in serous ovarian cancer.

Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR.

J Ovarian Res. 2014 Nov 4;7:95. doi: 10.1186/s13048-014-0095-1. Review.

18.

The impact of vitrification on murine germinal vesicle oocyte In vitro maturation and aurora kinase A protein expression.

Doyle JO, Lee HJ, Selesniemi K, Styer AK, Rueda BR.

J Assist Reprod Genet. 2014 Dec;31(12):1695-702. doi: 10.1007/s10815-014-0336-7. Epub 2014 Oct 16.

19.

Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.

Friel AM, Zhang L, Pru CA, Clark NC, McCallum ML, Blok LJ, Shioda T, Peluso JJ, Rueda BR, Pru JK.

Cancer Lett. 2015 Jan 28;356(2 Pt B):434-42. doi: 10.1016/j.canlet.2014.09.036. Epub 2014 Oct 7.

20.

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.

Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7.

21.

The N-methyl-D-aspartate receptor, a precursor to N-methyl-D-aspartate receptor encephalitis, is found in the squamous tissue of ovarian teratomas.

Clark RM, Lynch MP, Kolp R, Zukerberg LR, Growdon WB, Rueda BR.

Int J Gynecol Pathol. 2014 Nov;33(6):598-606. doi: 10.1097/PGP.0000000000000104.

PMID:
25272299
22.

Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.

Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, Foster R, Rueda BR.

Front Oncol. 2014 Jul 7;4:171. doi: 10.3389/fonc.2014.00171. eCollection 2014.

23.

The anti-inflammatory impact of omega-3 polyunsaturated Fatty acids during the establishment of endometriosis-like lesions.

Attaman JA, Stanic AK, Kim M, Lynch MP, Rueda BR, Styer AK.

Am J Reprod Immunol. 2014 Oct;72(4):392-402. doi: 10.1111/aji.12276. Epub 2014 Jun 5.

PMID:
24898804
24.

MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?

Karmon AE, Cardozo ER, Rueda BR, Styer AK.

Hum Reprod Update. 2014 Sep-Oct;20(5):670-87. doi: 10.1093/humupd/dmu017. Epub 2014 Apr 4. Review.

PMID:
24706045
25.

Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.

Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, Sathayanrayanan S, Foster R, Rueda BR, Growdon WB.

Gynecol Oncol. 2014 Jun;133(3):607-15. doi: 10.1016/j.ygyno.2014.03.560. Epub 2014 Mar 22.

PMID:
24667249
26.

Dendritic cells attenuate the early establishment of endometriosis-like lesions in a murine model.

Stanic AK, Kim M, Styer AK, Rueda BR.

Reprod Sci. 2014 Oct;21(10):1228-36. doi: 10.1177/1933719114525267. Epub 2014 Mar 4.

PMID:
24594835
27.

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.

Gynecol Oncol. 2014 May;133(2):346-52. doi: 10.1016/j.ygyno.2014.02.022. Epub 2014 Feb 19.

PMID:
24561032
28.

Adrenomedullin is a therapeutic target in colorectal cancer.

Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC.

Int J Cancer. 2014 May 1;134(9):2041-50. doi: 10.1002/ijc.28542. Epub 2013 Nov 7.

29.

Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum.

Young BC, Stanic AK, Panda B, Rueda BR, Panda A.

Am J Obstet Gynecol. 2014 May;210(5):445.e1-6. doi: 10.1016/j.ajog.2013.11.037. Epub 2013 Nov 28.

30.

Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits.

Fallon EM, Nehra D, Carlson SJ, Brown DW, Nedder AP, Rueda BR, Puder M.

J Surg Res. 2014 Mar;187(1):101-6. doi: 10.1016/j.jss.2013.10.016. Epub 2013 Oct 12.

PMID:
24189178
31.

Identification of LMX1B as a novel oncogene in human ovarian cancer.

He L, Guo L, Vathipadiekal V, Sergent PA, Growdon WB, Engler DA, Rueda BR, Birrer MJ, Orsulic S, Mohapatra G.

Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.

PMID:
24056967
32.

Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice.

Arnason T, Pino MS, Yilmaz O, Kirley SD, Rueda BR, Chung DC, Zukerberg LR.

Cancer Biol Ther. 2013 Jul;14(7):672-8. doi: 10.4161/cbt.25089. Epub 2013 May 31.

33.

Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.

Kulkarni-Datar K, Orsulic S, Foster R, Rueda BR.

Cancer Lett. 2013 Oct 10;339(2):237-46. doi: 10.1016/j.canlet.2013.06.014. Epub 2013 Jun 18.

PMID:
23791886
34.

No REST for fibroids.

Rueda BR, Davis JS.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):1980-1. doi: 10.1073/pnas.1222730110. Epub 2013 Jan 25. No abstract available.

35.

Ovarian cancer stem cells: working towards the root of stemness.

Foster R, Buckanovich RJ, Rueda BR.

Cancer Lett. 2013 Sep 10;338(1):147-57. doi: 10.1016/j.canlet.2012.10.023. Epub 2012 Nov 5. Review.

PMID:
23138176
36.

Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids.

Nehra D, Le HD, Fallon EM, Carlson SJ, Woods D, White YA, Pan AH, Guo L, Rodig SJ, Tilly JL, Rueda BR, Puder M.

Aging Cell. 2012 Dec;11(6):1046-54. doi: 10.1111/acel.12006. Epub 2012 Oct 19.

37.

Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.

Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ.

PLoS One. 2012;7(7):e41593. doi: 10.1371/journal.pone.0041593. Epub 2012 Jul 24.

38.

Sunitinib reduces recurrent pelvic adhesions in a rabbit model.

Fallon EM, Nehra D, Carlson SJ, Potemkin AK, Mitchell PD, Nedder AP, Rueda BR, Puder M.

J Surg Res. 2012 Dec;178(2):860-5. doi: 10.1016/j.jss.2012.07.038. Epub 2012 Aug 1.

PMID:
22884447
39.

Effect of sunitinib on functional reproductive outcome in a rabbit model.

Fallon EM, Nehra D, Le HD, Nedder AP, Guo L, Mitchell PD, Rueda BR, Puder M.

Fertil Steril. 2012 Aug;98(2):496-502. doi: 10.1016/j.fertnstert.2012.05.020. Epub 2012 Jun 13.

PMID:
22698641
40.

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM.

Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5.

41.

Dendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors.

Panda B, Panda A, Ueda I, Abrahams VM, Norwitz ER, Stanic AK, Young BC, Ecker JL, Altfeld M, Shaw AC, Rueda BR.

J Reprod Immunol. 2012 Jun;94(2):210-5. doi: 10.1016/j.jri.2012.01.008. Epub 2012 Mar 21.

PMID:
22440523
42.

Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G.

PLoS One. 2012;7(2):e30996. doi: 10.1371/journal.pone.0030996. Epub 2012 Feb 15.

43.

Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Burgos-Ojeda D, Rueda BR, Buckanovich RJ.

Cancer Lett. 2012 Sep 1;322(1):1-7. doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11. Review.

44.

Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.

McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR.

PLoS One. 2011;6(11):e28077. doi: 10.1371/journal.pone.0028077. Epub 2011 Nov 29.

45.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13. doi: 10.1073/pnas.1111840108. Epub 2011 Nov 8.

46.

Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation.

Sabatini ME, Guo L, Lynch MP, Doyle JO, Lee H, Rueda BR, Styer AK.

J Ovarian Res. 2011 May 23;4(1):8. doi: 10.1186/1757-2215-4-8.

47.

cables1 is required for embryonic neural development: molecular, cellular, and behavioral evidence from the zebrafish.

Groeneweg JW, White YA, Kokel D, Peterson RT, Zukerberg LR, Berin I, Rueda BR, Wood AW.

Mol Reprod Dev. 2011 Jan;78(1):22-32. doi: 10.1002/mrd.21263. Epub 2010 Dec 23.

48.

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer.

Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR.

Front Biosci (Landmark Ed). 2011 Jan 1;16:368-92. Review.

PMID:
21196176
49.

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.

Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR.

Gynecol Oncol. 2011 Apr;121(1):212-7. doi: 10.1016/j.ygyno.2010.11.039. Epub 2010 Dec 17.

PMID:
21168197
50.

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.

Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR.

Reprod Biol Endocrinol. 2010 Dec 1;8:147. doi: 10.1186/1477-7827-8-147.

Supplemental Content

Loading ...
Support Center